View Future GrowthRegent Pacific Group 과거 순이익 실적과거 기준 점검 0/6Regent Pacific Group은 연평균 12.9%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 연평균 9.4%의 비율로 증가했습니다. 매출은 연평균 50.4%의 비율로 감소했습니다.핵심 정보12.92%순이익 성장률25.37%주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률5.95%매출 성장률-50.42%자기자본이익률n/a순이익률-1,297.52%최근 순이익 업데이트31 Dec 2025최근 과거 실적 업데이트공시 • Mar 16Regent Pacific Group Limited to Report Fiscal Year 2025 Results on Mar 26, 2026Regent Pacific Group Limited announced that they will report fiscal year 2025 results at 12:30 PM, China Standard Time on Mar 26, 2026공시 • Aug 15Regent Pacific Group Limited to Report First Half, 2025 Results on Aug 27, 2025Regent Pacific Group Limited announced that they will report first half, 2025 results on Aug 27, 2025공시 • Mar 17Regent Pacific Group Limited to Report Fiscal Year 2024 Results on Mar 27, 2025Regent Pacific Group Limited announced that they will report fiscal year 2024 results on Mar 27, 2025공시 • Aug 16Regent Pacific Group Limited to Report First Half, 2024 Results on Aug 28, 2024Regent Pacific Group Limited announced that they will report first half, 2024 results on Aug 28, 2024공시 • Mar 16Regent Pacific Group Limited to Report Fiscal Year 2023 Results on Mar 27, 2024Regent Pacific Group Limited announced that they will report fiscal year 2023 results on Mar 27, 2024공시 • Aug 18Regent Pacific Group Limited to Report First Half, 2023 Results on Aug 29, 2023Regent Pacific Group Limited announced that they will report first half, 2023 results on Aug 29, 2023모든 업데이트 보기Recent updates공시 • May 07Regent Pacific Group Limited, Annual General Meeting, May 29, 2026Regent Pacific Group Limited, Annual General Meeting, May 29, 2026, at 15:00 China Standard Time. Location: room 302, 3/f, first commercial building, 33-35 leighton road, causeway bay, Hong Kong공시 • Mar 16Regent Pacific Group Limited to Report Fiscal Year 2025 Results on Mar 26, 2026Regent Pacific Group Limited announced that they will report fiscal year 2025 results at 12:30 PM, China Standard Time on Mar 26, 2026공시 • Aug 15Regent Pacific Group Limited to Report First Half, 2025 Results on Aug 27, 2025Regent Pacific Group Limited announced that they will report first half, 2025 results on Aug 27, 2025공시 • Jun 30Regent Pacific Group Limited Announces Change in Composition of the Nomination CommitteeRegent Pacific Group Limited announced that Mrs. Jayne Sutcliffe, a Non-Executive Director, and Mr. Ihsan Al Chalabi, an Independent Non-Executive Director, have been appointed as a member of the nomination committee of the Company (the "Nomination Committee") with effect from 30 June 2025. Following the above changes, the composition of the Nomination Committee comprises five members, namely James Mellon (Chairman of the Nomination Committee), Jayne Sutcliffe, Mark Searle, Adrian Chan and Ihsan Al Chalabi.공시 • Apr 28Regent Pacific Group Limited, Annual General Meeting, Jun 19, 2025Regent Pacific Group Limited, Annual General Meeting, Jun 19, 2025, at 15:00 China Standard Time. Location: 14/f, fairmont house, 8 cotton tree drive, central, Hong Kong공시 • Mar 17Regent Pacific Group Limited to Report Fiscal Year 2024 Results on Mar 27, 2025Regent Pacific Group Limited announced that they will report fiscal year 2024 results on Mar 27, 2025공시 • Dec 19Regent Pacific Group Limited Announces Submission of Senstend New Drug Application to the National Medical Products Administration in ChinaThe Board announced that commercial strategic partner Jiang Su Wan Bang Sheng Hua Yi Yao Ji Tuan You Xian Ze Ren Gong Si (Jiangsu Wanbang Biopharmaceutical Group Co. Ltd.) ("Wanbang Biopharmaceutical", a wholly-controlled company of Shanghai Fosun Pharmaceutical (Group) Co. Ltd. ("Fosun")) has submitted the New Drug Application ("NDA") registration dossier with the National Medical Products Administration ("NMPA") on 17 December 2024, with approval expected within 12 months from the submission date. Wanbang Biopharmaceutical is responsible, at its own expense, for obtaining the NDA from NMPA and maintaining any and all regulatory approvals required for the importation of Senstend in the People's Republic of China ("China" or "PRC"). In addition, and importantly, Wanbang Biopharmaceutical has signed an exclusive manufacturing and supply agreement with, inter alia, Genetic S.p. A. ("Genetic") and Jiang Su Wan Bang Yi Yao Ying Xiao You Xian Gong Si (Wanbang Pharmaceutical Marketing and Distribution Co. Ltd) ("Wanbang MKT", an affiliate of Wanbang Biopharmaceutical) on 26 August 2024, where Genetic will manufacture and supply Senstend to Wanbang Biopharmaceutical based on purchase orders received from Wanbang Biopharmaceutical. As previously mentioned, on the NDA being approved by NMPA, USD 5 million (or approximately HKD 39 million) and on first commercial launch USD 2 million (or approximately HKD 15.60 million) will be payable to the Group from Wanbang Biopharm pharmaceutical.공시 • Aug 16Regent Pacific Group Limited to Report First Half, 2024 Results on Aug 28, 2024Regent Pacific Group Limited announced that they will report first half, 2024 results on Aug 28, 2024공시 • Apr 28Regent Pacific Group Limited, Annual General Meeting, May 30, 2024Regent Pacific Group Limited, Annual General Meeting, May 30, 2024, at 15:00 China Standard Time. Location: 14/F, Fairmont House, 8 Cotton Tree Drive, Central Hong Kong Agenda: To receive, consider and adopt the audited financial statements of the Company and the reports of the Directors and the independent auditor of the Company for the year ended 31 December 2023; to re-appoint RSM Hong Kong as the independent auditor of the Company and to authorise the Board to fix their remuneration; to re-elect the following Directors, each as a separate ordinary resolution, and to authorise the Board to fix the remuneration of the Directors for the year ending 31 December 2024; and to consider other matters.공시 • Mar 26Qujing Black Gold Energy Co., Ltd. entered into a sale and purchase agreement to acquire 25% stake in West China Coking & Gas Company Limited from Regent Pacific Group Limited (SEHK:575) for CNY 8 million.Qujing Black Gold Energy Co., Ltd. entered into a sale and purchase agreement to acquire 25% stake in West China Coking & Gas Company Limited from Regent Pacific Group Limited (SEHK:575) for CNY 8 million on March 24, 2024. The consideration consists of CNY 8 million in cash. As part of the consideration, CNY 8 million was paid towards common equity. . West China Coking & Gas Company Limited reported the unaudited net loss of CNY 8.9 million as at 31 December 2023. The completion of the transaction is conditional upon all necessary corporate, governmental or regulatory approvals of the Disposal (the “Conditions”) including but not limited to unanimous approval from the shareholders of the Target Company and any relevant PRC governmental or regulatory bodies.공시 • Mar 16Regent Pacific Group Limited to Report Fiscal Year 2023 Results on Mar 27, 2024Regent Pacific Group Limited announced that they will report fiscal year 2023 results on Mar 27, 2024공시 • Aug 18Regent Pacific Group Limited to Report First Half, 2023 Results on Aug 29, 2023Regent Pacific Group Limited announced that they will report first half, 2023 results on Aug 29, 2023공시 • Jul 23Regent Pacific Group Limited Provides Consolidated Earnings Guidance for the Period Ended 30 June 2023Regent Pacific Group Limited provided consolidated earnings guidance for the period ended 30 June 2023. The group expects to record a loss attributable to the equity holders of the company for the period ended 30 June 2023 (the "Reporting Period") of between approximately USD 12 million (or approximately HKD 93.60 million) to approximately USD 15 million (or approximately HKD 117 million), which represents a substantial decrease in the loss as compared to a loss attributable to the equity holders of the Company of approximately USD 20.06 million (or approximately HKD 156.47 million) for the period ended 30 June 2022 (the "Corresponding Period").공시 • Feb 18Endurance RP Limited Provides Earnings Guidance for the Year Ended 31 December 2022Endurance RP Limited provided earnings guidance for the year ended 31 December 2022. For the year, the Group expects to record a loss attributable to the equity holders of the Company of between approximately USD 33 million (or approximately HKD 257.40 million) to approximately USD 36 million (or approximately HKD 280.80 million), which represents a substantial increase in the loss as compared to the loss attributable to the equity holders of the Company of approximately USD12.60 million (or approximately HKD 98.28 million) for the year ended 31 December 2021 (the Corresponding Period).매출 및 비용 세부 내역Regent Pacific Group가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이OTCPK:RPGL.F 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비31 Dec 250-54030 Sep 251-44030 Jun 251-44031 Mar 251-44031 Dec 241-44030 Sep 240-104030 Jun 240-154031 Mar 240-204031 Dec 230-254030 Sep 230-274030 Jun 230-294031 Mar 230-324031 Dec 220-364030 Sep 220-364-130 Jun 220-354-231 Mar 222-245-131 Dec 213-135030 Sep 214-46130 Jun 21556231 Mar 213-95131 Dec 202-245030 Sep 201-475030 Jun 200-705031 Mar 200-686031 Dec 190-666030 Sep 191-536030 Jun 191-406031 Mar 194-366031 Dec 186-316030 Sep 188-276030 Jun 1810-236031 Mar 188-256031 Dec 175-276030 Sep 173-326030 Jun 170-376031 Mar 170-207031 Dec 160-28030 Sep 16028030 Jun 16078031 Mar 160-18031 Dec 150-98030 Sep 153-158130 Jun 156-2273양질의 수익: RPGL.F 은(는) 현재 수익성이 없습니다.이익 마진 증가: RPGL.F는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: RPGL.F는 수익성이 없지만 지난 5년 동안 연평균 12.9%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 RPGL.F의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: RPGL.F은 수익성이 없어 지난 해 수익 성장률을 Pharmaceuticals 업계(-4.8%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: RPGL.F의 부채가 자산을 초과하여 자본 수익률을 계산하기 어렵습니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/15 19:28종가2026/03/18 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Regent Pacific Group Limited는 2명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Keith RedpathCavendishSanjay JhaHybridan LLP
공시 • Mar 16Regent Pacific Group Limited to Report Fiscal Year 2025 Results on Mar 26, 2026Regent Pacific Group Limited announced that they will report fiscal year 2025 results at 12:30 PM, China Standard Time on Mar 26, 2026
공시 • Aug 15Regent Pacific Group Limited to Report First Half, 2025 Results on Aug 27, 2025Regent Pacific Group Limited announced that they will report first half, 2025 results on Aug 27, 2025
공시 • Mar 17Regent Pacific Group Limited to Report Fiscal Year 2024 Results on Mar 27, 2025Regent Pacific Group Limited announced that they will report fiscal year 2024 results on Mar 27, 2025
공시 • Aug 16Regent Pacific Group Limited to Report First Half, 2024 Results on Aug 28, 2024Regent Pacific Group Limited announced that they will report first half, 2024 results on Aug 28, 2024
공시 • Mar 16Regent Pacific Group Limited to Report Fiscal Year 2023 Results on Mar 27, 2024Regent Pacific Group Limited announced that they will report fiscal year 2023 results on Mar 27, 2024
공시 • Aug 18Regent Pacific Group Limited to Report First Half, 2023 Results on Aug 29, 2023Regent Pacific Group Limited announced that they will report first half, 2023 results on Aug 29, 2023
공시 • May 07Regent Pacific Group Limited, Annual General Meeting, May 29, 2026Regent Pacific Group Limited, Annual General Meeting, May 29, 2026, at 15:00 China Standard Time. Location: room 302, 3/f, first commercial building, 33-35 leighton road, causeway bay, Hong Kong
공시 • Mar 16Regent Pacific Group Limited to Report Fiscal Year 2025 Results on Mar 26, 2026Regent Pacific Group Limited announced that they will report fiscal year 2025 results at 12:30 PM, China Standard Time on Mar 26, 2026
공시 • Aug 15Regent Pacific Group Limited to Report First Half, 2025 Results on Aug 27, 2025Regent Pacific Group Limited announced that they will report first half, 2025 results on Aug 27, 2025
공시 • Jun 30Regent Pacific Group Limited Announces Change in Composition of the Nomination CommitteeRegent Pacific Group Limited announced that Mrs. Jayne Sutcliffe, a Non-Executive Director, and Mr. Ihsan Al Chalabi, an Independent Non-Executive Director, have been appointed as a member of the nomination committee of the Company (the "Nomination Committee") with effect from 30 June 2025. Following the above changes, the composition of the Nomination Committee comprises five members, namely James Mellon (Chairman of the Nomination Committee), Jayne Sutcliffe, Mark Searle, Adrian Chan and Ihsan Al Chalabi.
공시 • Apr 28Regent Pacific Group Limited, Annual General Meeting, Jun 19, 2025Regent Pacific Group Limited, Annual General Meeting, Jun 19, 2025, at 15:00 China Standard Time. Location: 14/f, fairmont house, 8 cotton tree drive, central, Hong Kong
공시 • Mar 17Regent Pacific Group Limited to Report Fiscal Year 2024 Results on Mar 27, 2025Regent Pacific Group Limited announced that they will report fiscal year 2024 results on Mar 27, 2025
공시 • Dec 19Regent Pacific Group Limited Announces Submission of Senstend New Drug Application to the National Medical Products Administration in ChinaThe Board announced that commercial strategic partner Jiang Su Wan Bang Sheng Hua Yi Yao Ji Tuan You Xian Ze Ren Gong Si (Jiangsu Wanbang Biopharmaceutical Group Co. Ltd.) ("Wanbang Biopharmaceutical", a wholly-controlled company of Shanghai Fosun Pharmaceutical (Group) Co. Ltd. ("Fosun")) has submitted the New Drug Application ("NDA") registration dossier with the National Medical Products Administration ("NMPA") on 17 December 2024, with approval expected within 12 months from the submission date. Wanbang Biopharmaceutical is responsible, at its own expense, for obtaining the NDA from NMPA and maintaining any and all regulatory approvals required for the importation of Senstend in the People's Republic of China ("China" or "PRC"). In addition, and importantly, Wanbang Biopharmaceutical has signed an exclusive manufacturing and supply agreement with, inter alia, Genetic S.p. A. ("Genetic") and Jiang Su Wan Bang Yi Yao Ying Xiao You Xian Gong Si (Wanbang Pharmaceutical Marketing and Distribution Co. Ltd) ("Wanbang MKT", an affiliate of Wanbang Biopharmaceutical) on 26 August 2024, where Genetic will manufacture and supply Senstend to Wanbang Biopharmaceutical based on purchase orders received from Wanbang Biopharmaceutical. As previously mentioned, on the NDA being approved by NMPA, USD 5 million (or approximately HKD 39 million) and on first commercial launch USD 2 million (or approximately HKD 15.60 million) will be payable to the Group from Wanbang Biopharm pharmaceutical.
공시 • Aug 16Regent Pacific Group Limited to Report First Half, 2024 Results on Aug 28, 2024Regent Pacific Group Limited announced that they will report first half, 2024 results on Aug 28, 2024
공시 • Apr 28Regent Pacific Group Limited, Annual General Meeting, May 30, 2024Regent Pacific Group Limited, Annual General Meeting, May 30, 2024, at 15:00 China Standard Time. Location: 14/F, Fairmont House, 8 Cotton Tree Drive, Central Hong Kong Agenda: To receive, consider and adopt the audited financial statements of the Company and the reports of the Directors and the independent auditor of the Company for the year ended 31 December 2023; to re-appoint RSM Hong Kong as the independent auditor of the Company and to authorise the Board to fix their remuneration; to re-elect the following Directors, each as a separate ordinary resolution, and to authorise the Board to fix the remuneration of the Directors for the year ending 31 December 2024; and to consider other matters.
공시 • Mar 26Qujing Black Gold Energy Co., Ltd. entered into a sale and purchase agreement to acquire 25% stake in West China Coking & Gas Company Limited from Regent Pacific Group Limited (SEHK:575) for CNY 8 million.Qujing Black Gold Energy Co., Ltd. entered into a sale and purchase agreement to acquire 25% stake in West China Coking & Gas Company Limited from Regent Pacific Group Limited (SEHK:575) for CNY 8 million on March 24, 2024. The consideration consists of CNY 8 million in cash. As part of the consideration, CNY 8 million was paid towards common equity. . West China Coking & Gas Company Limited reported the unaudited net loss of CNY 8.9 million as at 31 December 2023. The completion of the transaction is conditional upon all necessary corporate, governmental or regulatory approvals of the Disposal (the “Conditions”) including but not limited to unanimous approval from the shareholders of the Target Company and any relevant PRC governmental or regulatory bodies.
공시 • Mar 16Regent Pacific Group Limited to Report Fiscal Year 2023 Results on Mar 27, 2024Regent Pacific Group Limited announced that they will report fiscal year 2023 results on Mar 27, 2024
공시 • Aug 18Regent Pacific Group Limited to Report First Half, 2023 Results on Aug 29, 2023Regent Pacific Group Limited announced that they will report first half, 2023 results on Aug 29, 2023
공시 • Jul 23Regent Pacific Group Limited Provides Consolidated Earnings Guidance for the Period Ended 30 June 2023Regent Pacific Group Limited provided consolidated earnings guidance for the period ended 30 June 2023. The group expects to record a loss attributable to the equity holders of the company for the period ended 30 June 2023 (the "Reporting Period") of between approximately USD 12 million (or approximately HKD 93.60 million) to approximately USD 15 million (or approximately HKD 117 million), which represents a substantial decrease in the loss as compared to a loss attributable to the equity holders of the Company of approximately USD 20.06 million (or approximately HKD 156.47 million) for the period ended 30 June 2022 (the "Corresponding Period").
공시 • Feb 18Endurance RP Limited Provides Earnings Guidance for the Year Ended 31 December 2022Endurance RP Limited provided earnings guidance for the year ended 31 December 2022. For the year, the Group expects to record a loss attributable to the equity holders of the Company of between approximately USD 33 million (or approximately HKD 257.40 million) to approximately USD 36 million (or approximately HKD 280.80 million), which represents a substantial increase in the loss as compared to the loss attributable to the equity holders of the Company of approximately USD12.60 million (or approximately HKD 98.28 million) for the year ended 31 December 2021 (the Corresponding Period).